Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population

Gene

Volumn 527, Issue 1, 2013, Pages 360-365

  Jin, Tian Bo ^a,b,c   Ma, Li Feng ^a   Zhang, Jia Yi ^b   Yuan, Dong Ya ^a   Sun, Qiang ^b   Zong, Ting Yong ^b   Geng, Ting Ting ^c   Cui, Ya Li ^d   Kang, Long Li ^a   Chen, Chao ^b,e  

^a XIZANG MINZU UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c Shaanxi Lifegen Co Ltd   (China)

^d Xi'an GoldMag Nanobiotech Co Ltd   (China)

^e not available   (China)

Author keywords

CYP2D6; Ethnic difference; Genetic polymorphism; Haplotype; Tibetan

Indexed keywords

CYTOCHROME P450 2D6;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; ENDOPLASMIC RETICULUM; EXON; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION;

EID: 84881222406     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.110     Document Type: Article

References (31)

1. Adamec C. Example of the use of the nonparametric test. Test X2 for comparison of 2 independent examples. Cesk. Zdrav. 1964, 12:613-619.
2. Baclig M.O., et al. Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines. Int. J. Mol. Epidemiol. Genet. 2012, 3:115-121.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Bertilsson L., et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 1992, 51:388-397.
5. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
6. Duan P., et al. Effect of neuronal induction on NSE, Tau, and Oct4 promoter methylation in bone marrow mesenchymal stem cells. In Vitro Cell. Dev. Biol. Anim. 2012, 48:251-258.
7. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006, 57:119-137.
8. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
9. Gaedigk A., Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. 2008, 64:465-475.
10. Garcia-Barcelo M., et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 2000, 46:18-23.
11. Hersberger M., Marti-Jaun J., Rentsch K., Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin. Chem. 2000, 46:1072-1077.
12. Ji L., Pan S., Wu J., Marti-Jaun J., Hersberger M. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin. Med. J. (Engl.) 2002, 115:1780-1784.
13. Leathart J.B., et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998, 8:529-541.
14. Lee E.J., Nam Y.P., Hee G.N. Oxidation phenotyping in Chinese and Malay populations. Clin. Exp. Pharmacol. Physiol. 1988, 15:889-891.
15. Lee S.Y., et al. Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit. 2006, 28:382-387.
16. Lovlie R., Daly A.K., Molven A., Idle J.R., Steen V.M. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996, 392:30-34.
17. Meyer U.A. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1983-1984.
18. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet 2000, 356:1667-1671.
19. Miners J.O., Day R.O. Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes. Br. J. Clin. Pharmacol. 2007, 63:380-381. (author reply 381-382).
20. Mirfakhrai M., Tanaka Y., Yanagisawa K. Evidence for mitochondrial DNA polymorphism and uniparental inheritance in the cellular slime mold Polysphondylium pallidum: effect of intraspecies mating on mitochondrial DNA transmission. Genetics 1990, 124:607-613.
21. Nelson D.R., et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004, 14:1-18.
22. Nishida Y., Fukuda T., Yamamoto I., Azuma J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 2000, 10:567-570.
23. Otton S.V., et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 1993, 54:463-472.
24. Panserat S., et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum. Genet. 1994, 94:401-406.
25. Qin S., et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 2008, 92:152-158.
26. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997, 60:284-295.
27. Scordo M.G., Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002, 3:201-218.
28. Sternberg T.G., DM, Thompson J.W., Schoumacher R.A., Lew D.B. Recurrent stridor in a 9-year-old child after a choking and aspiration event. Allergy Asthma Proc. 2009, 31:154-157.
29. Teh L.K., et al. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J. Clin. Pharm. Ther. 2001, 26:205-211.
30. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokinet. 2009, 48:689-723.
31. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet. 2009, 48:761-804.